RSV Vaccine for Babies and Children: What To Know

First, Is There an RSV Vaccine for Babies?

There is currently no routine RSV vaccine approved for infants or young children in the United States. RSV vaccines such as Abrysvo, Arexvy, and mResvia are intended for specific adult populations, and only Pfizer’s Abrysvo is recommended during pregnancy to protect an infant after birth.

Babies can instead receive one of two long-acting RSV antibody products: nirsevimab, sold as Beyfortus, or clesrovimab, sold as Enflonsia. These products supply ready-made antibodies rather than teaching the baby’s immune system to manufacture antibodies. Protection begins quickly and is designed to last through a typical RSV season.

Calling every RSV injection a “vaccine” is understandable, but medically the distinction matters. Vaccines create active immunity. Monoclonal antibodies create passive immunity. Think of a vaccine as teaching the immune system how to build its own umbrella, while an antibody product hands the baby an umbrella that is already open.

Why RSV Protection Matters

RSV is extremely common. Almost every child is infected at least once by age two, and many infections remain mild. The greatest concern is the first several months of life, when a baby’s airways are narrow and respiratory illness can become serious quickly.

Before universal infant protection was recommended, RSV was the leading cause of hospitalization among American infants. An estimated 58,000 to 80,000 children younger than five were hospitalized with RSV annually, and hospitalization risk was highest during the first six months of life. Importantly, many hospitalized infants had no known underlying medical condition. A healthy-looking newborn does not receive a magical “RSV cannot find me” shield at discharge.

Most RSV infections cause congestion, coughing, sneezing, fever, fussiness, or reduced feeding. More serious illness may cause bronchiolitis or pneumonia. Babies can develop rapid breathing, wheezing, grunting, nostril flaring, pauses in breathing, or chest retractions in which the skin pulls inward around the ribs or neck.

Who Should Receive RSV Protection?

Current U.S. guidance aims to protect essentially every infant entering a first RSV season through one of two strategies:

• Maternal RSV vaccination during an eligible pregnancy, or
• A long-acting RSV antibody administered directly to the infant.

Most babies do not need both approaches. The choice depends on pregnancy timing, the baby’s birth date, whether maternal vaccination occurred, product availability, local RSV circulation, and individual medical circumstances.

Option 1: RSV Vaccination During Pregnancy

CDC recommends one dose of Pfizer’s Abrysvo during 32 weeks through 36 weeks and 6 days of pregnancy. In most of the continental United States, it is given seasonally from September through January. The pregnant patient’s immune system produces RSV antibodies, which cross the placenta and help protect the baby during early infancy.

Timing matters because the body needs time to develop antibodies and transfer them to the fetus. At least 14 days are generally needed between vaccination and delivery. A baby born fewer than 14 days after maternal vaccination should usually receive an infant RSV antibody because adequate protection may not have transferred before birth.

For example, suppose a parent receives Abrysvo on December 15 and delivers on January 8. More than 14 days have passed, so the baby generally would not need an additional RSV antibody. If delivery occurred on December 22, only seven days after vaccination, an infant antibody would ordinarily be recommended.

CDC does not currently recommend repeating maternal RSV vaccination during a later pregnancy if the patient received it during any previous pregnancy. In that situation, the baby from the later pregnancy should receive an infant monoclonal antibody when eligible. Recommendations may evolve as additional data become available, so previous vaccination history should always be discussed with the obstetric and pediatric care teams.

Option 2: An RSV Antibody for the Baby

An infant younger than eight months who is born during or entering a first RSV season should receive nirsevimab or clesrovimab when:

• The birth parent did not receive an RSV vaccine during the current pregnancy.
• The parent’s vaccination status is unknown.
• The baby was born fewer than 14 days after maternal vaccination.

In most of the continental United States, eligible babies born from October through March should receive the antibody within the first week after birth, ideally during the birth hospitalization. An eligible baby born from April through September can generally receive it shortly before the RSV season begins, often in October or November.

Consider a baby born in July whose parent was not vaccinated during pregnancy. The baby may receive an RSV antibody in the fall before seasonal RSV activity increases. A baby born in January may receive it before leaving the hospital. Both babies are entering their first RSV season; their calendars simply look different.

RSV timing varies in Alaska, Hawaii, southern Florida, Puerto Rico, Guam, the U.S. Virgin Islands, and other locations with tropical, prolonged, or unpredictable RSV circulation. Local health departments and clinicians may adjust administration dates based on regional surveillance.

When Might a Baby Receive Both Forms of Protection?

Although most infants need only maternal vaccination or an infant antibody, a pediatrician may consider an antibody for a baby whose parent was vaccinated when special circumstances could have reduced protection. Examples include impaired maternal immune response, reduced transfer of antibodies across the placenta, cardiopulmonary bypass, exchange transfusion, or an exceptionally high risk of severe RSV disease. These decisions require individual clinical judgment rather than a one-size-fits-all checklist.

Which Children Need Protection During a Second RSV Season?

Healthy children eight months and older generally do not need an RSV antibody. As children grow, their airways become larger and their risk of severe RSV disease usually declines.

Nirsevimab is recommended for certain children ages eight through 19 months who are entering a second RSV season and remain at increased risk. Eligible groups include:

• Children with chronic lung disease of prematurity who recently required oxygen, diuretics, or corticosteroid treatment.
• Children with severe immunocompromise.
• Children with cystic fibrosis and severe lung disease or poor growth.
• American Indian or Alaska Native children.

Clesrovimab is intended for the first RSV season and is not recommended for children entering a second season. CDC does not currently recommend nirsevimab for anyone age 20 months or older.

Nirsevimab vs. Clesrovimab: What Is the Difference?

Both products are long-acting monoclonal antibodies given by intramuscular injection. Both are intended to prevent severe lower respiratory tract disease rather than treat an RSV infection that has already started.

CDC and the American Academy of Pediatrics do not generally prefer one first-season product over the other when both are medically appropriate. Availability, hospital supply, insurance arrangements, the baby’s age, and the clinician’s recommendation may determine which one is used.

How Effective Are RSV Immunizations?

These products substantially reduce the risk of medically attended RSV disease and hospitalization, but they do not guarantee that a baby will never become infected.

Clinical trials found that maternal RSV vaccination reduced infant hospitalization from RSV by approximately 57% during the first six months after birth. It also reduced severe infant outcomes, including low blood oxygen, intensive care admission, and mechanical ventilation.

Recent U.S. surveillance from the 2024–2025 season estimated that maternal vaccination was 70% effective against RSV hospitalization among young infants. Nirsevimab was estimated to be 81% effective against hospitalization and continued to provide substantial protection several months after administration. Population-level hospitalization rates among babies younger than one year fell by as much as half compared with seasons before these products were introduced.

In clinical studies, clesrovimab reduced medically attended RSV lower respiratory tract illness and showed approximately 91% efficacy against RSV-associated hospitalization through about five months of follow-up. Percentages from different trials should not be compared as though they came from one giant head-to-head contest; study populations, definitions, seasons, and methods differ.

The practical takeaway is simpler: RSV protection makes severe disease and hospitalization much less likely, but parents should still watch for symptoms.

Are RSV Vaccines and Antibody Shots Safe?

Maternal RSV Vaccine Safety

Common reactions after Abrysvo during pregnancy include injection-site pain, headache, muscle aches, and nausea. These effects are generally temporary.

In the original clinical trial, researchers observed a numerical difference in preterm births between vaccinated and placebo groups, although the available data did not establish that the vaccine caused preterm delivery. The FDA limited the pregnancy indication to weeks 32 through 36 to reduce potential risk, and safety monitoring continues. Clinical guidance concludes that the expected benefits during the recommended window outweigh the known potential risks.

Abrysvo should not be given to someone who has experienced a severe allergic reaction to one of its ingredients. A mild illness such as a simple cold is not usually a reason to delay vaccination, but a moderate or severe illness may warrant waiting until recovery.

Infant RSV Antibody Safety

Side effects from nirsevimab or clesrovimab are usually mild. Nirsevimab may cause a rash or an injection-site reaction. Reported clesrovimab reactions include redness, swelling, rash, temporary irritability, or sleepiness. Serious allergic reactions are possible but uncommon.

Neither antibody should be administered to a child with a known history of severe allergic reaction to the product or one of its components. A baby with a moderate or severe acute illness may be advised to recover before receiving the injection.

Can the RSV Antibody Be Given With Routine Childhood Vaccines?

Yes. Nirsevimab or clesrovimab can be administered during the same appointment as routine childhood vaccines. No waiting period is required between an RSV antibody and live vaccines such as measles, mumps, and rubella or varicella vaccine.

Maternal Abrysvo can also be given during the same visit as influenza, COVID-19, or Tdap vaccination when those vaccines are due. Receiving several shots at one appointment may not be anyone’s idea of a spa afternoon, but it can reduce missed opportunities for protection.

What RSV Protection Does Not Do

RSV vaccination during pregnancy and infant monoclonal antibodies are preventive tools. They do not treat an active RSV infection, cure bronchiolitis, or instantly stop coughing.

Protection also decreases gradually over time. The goal is to cover the baby during the first RSV season, especially the earliest months when hospitalization risk is highest. Children can still catch RSV after immunization, and people can be infected more than once.

Families should continue using everyday preventive habits: wash hands, clean frequently touched surfaces, avoid tobacco smoke, keep sick visitors away from newborns, and encourage household members to remain current on recommended vaccines.

When Should Parents Seek Medical Help?

Call a pediatrician promptly when a baby has worsening cough, wheezing, poor feeding, unusual sleepiness, dehydration, or signs that breathing is becoming difficult.

Seek urgent medical care for:

• Pauses in breathing or persistent difficulty breathing.
• Skin pulling inward between the ribs or below the neck.
• Blue, gray, or unusually pale lips, skin, or nail beds.
• Markedly reduced activity or difficulty waking the baby.
• Fewer than one wet diaper in eight hours.
• A rectal temperature of 100.4°F or higher in a baby younger than three months.

Immunization lowers risk, but it does not replace careful observation. Parents know their baby’s ordinary behavior better than anyone else; a dramatic change deserves attention.

Questions to Ask Your Healthcare Professional

• Was an RSV vaccine given during this pregnancy, and on what date?
• Will at least 14 days pass between maternal vaccination and expected delivery?
• Will my baby be born during or shortly before the local RSV season?
• Will nirsevimab or clesrovimab be available at the birth hospital?
• Does my child qualify for protection during a second RSV season?
• Can the RSV antibody be given at the same visit as scheduled childhood vaccines?
• Which symptoms should prompt a same-day call or emergency evaluation?

Writing down vaccination dates is especially useful. “Sometime around the holidays” is charming in a family story but less useful when a pediatrician is calculating whether 14 days elapsed before delivery.

Practical Experiences: What RSV Protection Decisions Can Look Like

The following examples are illustrative family scenarios rather than individual medical case reports. They show how timing and communication can affect the decision.

Experience 1: The Winter Baby With Maternal Protection

A first-time parent expects to deliver in early January. At 33 weeks of pregnancy, the obstetrician explains that the baby will arrive during peak respiratory virus season. The parent receives Abrysvo in early December and records the date in a phone calendar.

The baby arrives more than three weeks later. During the birth hospitalization, the pediatric team confirms that maternal vaccination occurred within the recommended pregnancy window and more than 14 days before delivery. Unless another medical issue changes the decision, the newborn does not need a monoclonal antibody.

The useful lesson is not merely “get the shot.” It is to make sure the vaccination date follows the parent into the hospital record. Pregnancy and pediatric medical systems do not always share information perfectly, and exhausted new parents should not be expected to conduct a late-night archaeological dig through pharmacy receipts.

Experience 2: The Baby Who Arrives Earlier Than Planned

Another parent receives the maternal RSV vaccine at 34 weeks, expecting several more weeks before delivery. The baby, demonstrating an early commitment to ignoring schedules, is born nine days later.

Because fewer than 14 days passed, the pediatrician recommends an infant RSV antibody. This does not mean the maternal vaccine “failed.” It means the body may not have had enough time to produce and transfer the desired level of antibodies before birth.

The family initially worries that receiving both products will be excessive. The clinician explains that this is one of the circumstances specifically addressed by current guidance. The infant antibody supplies immediate protection that may not yet have been transferred through the placenta.

Experience 3: The Summer Baby Entering Fall

A healthy baby is born in July to a parent who did not receive an RSV vaccine during pregnancy. Nothing needs to happen on the baby’s second day of life simply because RSV exists. Instead, the pediatrician plans to administer an infant antibody shortly before local RSV activity normally rises.

At the two-month visit, the family confirms whether the pediatric office will stock nirsevimab or clesrovimab. At the fall appointment, the baby receives one product along with routine vaccines. The family is pleasantly surprised that no special spacing is required.

Experience 4: The Toddler With Additional Risk

A 14-month-old child born prematurely has chronic lung disease and recently needed supplemental oxygen. The parents assume that RSV immunization is only for newborns, but the pediatric pulmonologist explains that certain high-risk children qualify for nirsevimab when entering their second season.

This example highlights why age alone is not the whole story. Most healthy toddlers do not need RSV antibodies, but a limited group remains vulnerable because of lung disease, immune compromise, cystic fibrosis, or other recognized risk factors.

Across all four situations, the most successful experiences share three ingredients: early discussion, accurate vaccination records, and a clear plan before RSV season begins. Families do not need to memorize every dosage or regulatory detail. They do need to know which protection route is planned, when it should occur, and whom to call when the plan is unclear.

Conclusion

The phrase “RSV vaccine for babies” is convenient but not quite accurate. Most infants are protected through either an RSV vaccine given during pregnancy or a long-acting antibody given directly after birth. Both approaches are designed to reduce severe RSV disease during the months when babies face the greatest risk.

For most families, the decision comes down to timing. Maternal Abrysvo is given during weeks 32 through 36 of pregnancy in the recommended season. Nirsevimab or clesrovimab is used when maternal vaccination did not occur, occurred too close to delivery, or cannot be confirmed. Some high-risk children may also receive nirsevimab before a second RSV season.

No preventive product removes every possibility of infection, but these immunizations have meaningfully reduced RSV hospitalizations. A short conversation before delivery or before fall respiratory season can replace a great deal of confusion with a straightforward protection plan.